|Articles|October 1, 2016
- Pharmaceutical Executive-10-01-2016
- Volume 36
- Issue 10
Pharmaceutical Executive, October 2016 Issue (PDF)
Click the title above to open the Pharmaceutical Executive October 2016 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 9 years ago
Content Marketing’s Data Fail: Information Without Insight?almost 9 years ago
The Rise of the CFO Strategist: Balancing Numbers and Know-howabout 9 years ago
Steps Toward Rare Disease Successabout 9 years ago
‘Huge Sellers’ Herald Changes in Japan Drug Pricingabout 9 years ago
Real-World Evidence: From Volume to Valueabout 9 years ago
Pharma and the Peril of Europe’s Trade Policiesabout 9 years ago
New Challenge to IP Innovationabout 9 years ago
Major Changes Ahead for Drug User Feesabout 9 years ago
Country Report: Czech RepublicNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
2
Merck Planning $70 Billion Investment for US Expansion
3
Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings
4
FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps
5
